A Phase 4 interventional study of Perampanel Oral Tablet in Epilepsy, sponsored by University of Arizona. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-08-15.
Sponsored by University of Arizona · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing perampanel in Epilepsy — none open to participants now, 1 under way, none of them phase 3. perampanel · Epilepsy.
Among the 28 studies testing perampanel in Epilepsy, this one is the 20th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2018, is one of 10 in phase 4, and was the 17th registered.
1,850 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →None of the 28 studies testing perampanel in Epilepsy is open now. The open studies under Epilepsy, anywhere →
perampanel: first FDA approval 2012 (FYCOMPA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 112 (39%) set no upper age limit and 149 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2018.
This study's enrollment of 20 is below the median of 50 across 1,240 interventional studies indexed under Epilepsy.
Median enrollment 26 across the 27 interventional studies. Of the 25 that completed or were terminated, 16 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 28 have an industry lead sponsor. The 10 most frequent:
University of Arizona is the lead sponsor of 477 studies on the registry; 88 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 30 (59%) have results posted.
University of Arizona has 2 studies filed under Epilepsy — fewer than ten, so there is no comparison to draw.
1 of the studies testing perampanel in Epilepsy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04015141Eisai Inc.A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy | 2027-04-06 |
Add it to your calendar (.ics) → With an account.
Among the 28 studies testing perampanel in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will aim to improve retention and tolerability by slowing the initial titration rate of perampanel from a standard up-titration rate of 2 week intervals to a slower up-titration rate consisting of 3 week intervals. Subjects will be randomized to either perampanel, standard titration interval rate (Group A) or perampanel, slower titration interval rate (Group B).
A total of 60 subjects with a confirmed diagnosis of either partial onset or primary generalized epilepsy will be recruited into the trial. 30 subjects will initiate perampanel at a dose of 2 mg/day and titrate upwards every 2 weeks to a target dose of 6 mg/day. Subjects in this group will be designated Group A. The remaining 30 subjects will also begin perampanel at a dose of 2 mg/day but will titrate upwards every 3 weeks to a target dose of 6 mg/day and will be designated Group B.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Perampanel oral tablet: 2mg by mouth every 24 hours for two weeks, then up-titrated by 2 mg every two weeks to a target dose of 6 mg/day. Minimum total daily dose = 2 mg/day. Maximum daily dose is 12 mg/day. Total daily dose will be determined by the Investigator based on tolerability and seizure control.
Drug: Perampanel Oral Tablet
Perampanel oral tablet: 2mg by mouth every 24 hours for three weeks, then up-titrated by 2 mg every three weeks to a target dose of 6 mg/day. Minimum total daily dose = 2 mg/day. Maximum daily dose is 12 mg/day. Total daily dose will be determined by the Investigator based on tolerability and seizure control.
Drug: Perampanel Oral Tablet
Perampanel is an AMPA receptor blockade, that has shown to be efficacious for seizure reduction in both partial onset seizures and generalized tonic-clonic seizures. Perampanel was approved by the FDA in October 2012 as adjunctive treatment in patients with partial onset seizures. Additionally, in June 2015, Fycompa was approved as adjunctive therapy in patients with primary generalized tonic clonic seizures.
Also known as: Fycompa
The Percentage of Subjects Completing 52 Weeks of Adjunctive Therapy During the Maintenance Phase [Retention Rate].
Retention rate, which indirectly measures the therapeutic tolerance, will be measured at 52 weeks in each group.
Time frame: Up to 52 weeks
Incidence of Treatment-Emergent Adverse Events (TEAEs) Reported by the Subject or Observed by the Investigator [Safety and Tolerability].
Adverse events experienced in each group will be tabulated and the total percentage of subjects reporting adverse events will be calculated.
Time frame: Up to 52 weeks
Seizures Frequency Per Week
The average of seizures per week will be calculated starting at initial titration through final maintenance \[Efficacy\]."
Time frame: Up to 52 weeks
| Milestone | Fycompa 2 Week Titration Intervals | Fycompa 3 Week Titration Intervals |
|---|---|---|
| Started | 10 | 10 |
| Completed | 7 | 8 |
| Not completed | 3 | 2 |
Retention rate, which indirectly measures the therapeutic tolerance, will be measured at 52 weeks in each group.
| Participants | Fycompa 2 Week Titration Intervals | Fycompa 3 Week Titration Intervals |
|---|---|---|
| The Percentage of Subjects Completing 52 Weeks of Adjunctive Therapy During the Maintenance Phase [Retention Rate]. | 2 | 3 |
Adverse events experienced in each group will be tabulated and the total percentage of subjects reporting adverse events will be calculated.
| participants | Fycompa 2 Week Titration Intervals | Fycompa 3 Week Titration Intervals |
|---|---|---|
| Incidence of Treatment-Emergent Adverse Events (TEAEs) Reported by the Subject or Observed by the Investigator [Safety and Tolerability]. | 4 | 3 |
The average of seizures per week will be calculated starting at initial titration through final maintenance \[Efficacy\]."
| Seizures per week | Fycompa 2 Week Titration Intervals | Fycompa 3 Week Titration Intervals |
|---|---|---|
| Seizures Frequency Per Week | 0.912 ± 0.647 | 0.508 ± 0.887 |
Collected over Up to 52 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fycompa 2 Week Titration Intervals | 0/10 (0%) | 0/10 (0%) | 4/10 (40%) |
| Fycompa 3 Week Titration Intervals | 0/10 (0%) | 1/10 (10%) | 3/10 (30%) |
| Event | Fycompa 2 Week Titration Intervals | Fycompa 3 Week Titration Intervals |
|---|---|---|
| Intractable SeizuresNervous system disorders | 0/10 | 1/10 |
| Event | Fycompa 2 Week Titration Intervals | Fycompa 3 Week Titration Intervals |
|---|---|---|
| AngerPsychiatric disorders | 4/10 | 3/10 |
| DizzinessNervous system disorders | 2/10 | 3/10 |
| UnsteadinessNervous system disorders | 0/10 | 3/10 |
| Head coldInfections and infestations | 1/10 | 3/10 |
| DrowsinessNervous system disorders | 2/10 | 1/10 |
| Back painMusculoskeletal and connective tissue disorders | 2/10 | 1/10 |
| NumbnessNervous system disorders | 0/10 | 1/10 |
| NauseaGastrointestinal disorders | 1/10 | 1/10 |
| Memory difficultyNervous system disorders | 0/10 | 1/10 |
| AnxietyNervous system disorders | 1/10 | 0/10 |
| Age, Categorical(Participants) | Fycompa 2 Week Titration Intervals | Fycompa 3 Week Titration Intervals | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 10 | 10 | 20 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Fycompa 2 Week Titration Intervals | Fycompa 3 Week Titration Intervals | Total |
|---|---|---|---|
| Mean | 33 ± 11 | 43 ± 9 | 37 ± 11 |
| Sex: Female, Male(Participants) | Fycompa 2 Week Titration Intervals | Fycompa 3 Week Titration Intervals | Total |
|---|---|---|---|
| Female | 6 | 4 | 10 |
| Male | 4 | 6 | 10 |
| Race (NIH/OMB)(Participants) | Fycompa 2 Week Titration Intervals | Fycompa 3 Week Titration Intervals | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 8 | 10 | 18 |
| More than one race | 2 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Fycompa 2 Week Titration Intervals | Fycompa 3 Week Titration Intervals | Total |
|---|---|---|---|
| United States | 10 | 10 | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — At this time, there is no plan to share individual participant data with other researchers.
Ran from Apr 2018 to primary completion in Feb 2021, 34 months.
Results were first posted in Dec 2021, 9 months after primary completion.
Of 33 non-industry phase 4 interventional studies under Epilepsy, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 37. This study's 34 months is above that.
Counting every sponsor, half of 43 studies reached it within 25 months; a quarter within 12 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Perampanel